* Designed to help patients fall asleep, stay asleep * Merck's shares fall 1.1 percent to $45.47 By Toni Clarke May 20 (Reuters) - Merck & Co's experimental insomnia drug suvorexant appears genera…
May 20 (Reuters) - *FDA STAFF REVIEWERS SAY CLINICAL TRIALS OF MERCK'S SLEEP DRUG SUVOREXANT "OVERALL, ESTABLISH EFFECTIVENESS." *FDA STAFF REVIEWERS SAY SUVOREXANT SEEMS TO BE ASSOCIATED WITH EVENTS…
(Changes 'keep' to 'back overhaul of' in headline; changes wording of paragraph 7 to remove reference to retaining site)…
COPENHAGEN, May 17 (Reuters) - Denmark's Novo Nordisk , the world's biggest insulin producer, said on Friday it had completed the first phase III trial of a haemophilia drug, N9-GP.
